Explore The Oncology Institute's Q1 2025 earnings: 10% revenue growth, robust Dispensary performance, and a clear path to profitability by Q4.

Q1 2025 Management View CEO Phillip Chan reported that CytoSorbents is focused on three main areas: the performance and growth catalysts of the core CytoSorb business, regulatory status and plans for ...

BioCardia, Inc. ( NASDAQ: BCDA) Q1 2025 Earnings Conference Call May 14, 2025, 16:30 PM ET Peter Altman - President and CEO David McClung - CFO Miranda Peto - IR Joe Pantginis - H.C. Wainwright Laura ...

The latest health news highlights Sanofi's $20 billion U.S. investment through 2030, Merck's cancer drug expansion and the ...

Some U.S. biotech companies are considering moving early-stage trials of new medicines outside the United States as worry ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

This follows what appeared to be a generally positive data readout for belrestotug at ESMO 2024 just a few months ago.